Hadassah

Stem Cells and Platelets: Hadassah Pioneers Stroke Strategy

Monday, Jul 27 2015

The research team in Hadassah’s Peritz and Chantal Scheinberg Cerebrovascular Research Laboratory

The Hadassah Medical Center’s pioneering researchers are leading the way in exploring a novel cutting-edge stem cell treatment to reverse the disability a stroke leaves in its wake.

While the brain contains stem cells that are capable of some regeneration, the problem is that there are not enough of them and they don’t survive for a long time. To be effective in alleviating the damage cause by stroke, these stem cells need to be enhanced. 

Working with an animal model, the research team in Hadassah’s Peritz and Chantal Scheinberg Cerebrovascular Research Laboratory discovered a powerful enhancer: platelets shed microparticles which contain crucial growth factors that will trigger development of new blood cells and nerve cells, as well as repair and protect existing ones. The researchers, under the direction of Prof. Ronen Leker, head of the Scheinberg Laboratory and Hadassah’s Stroke Service, injected platelets into the cerebral hemispheres of the animal brain, providing a “supportive niche” for the existing stem cells to proliferate. (The platelets were harvested from old donations to the blood bank that were going to be discarded due to expiration date; however, Prof. Leker explains, any platelets can be used.)

The result: The platelets significantly increased the proliferation of the neural stem cells and the growth of new blood vessels, Prof. Leker reports. In addition, the rats experienced a reduction in the stroke-induced behavioral deficits.

The next step is testing the treatment in human trials. Incidence of stroke is 775,000 individuals annually in the United States, 1,000,000 in Europe, and 15,000 in Israel. Hadassah’s physicians use the latest techniques to treat stroke when the patients arrive at the hospital in time--stentreivers, for example, which pull the clot out of the blood vessel, leaving no neurological deficits. But many patients arrive at the hospital too late for physicians to prevent neurological losses.

Most strokes, Prof. Leker reports, are ischemic, where a blood vessel either leading to the brain or in the brain is blocked. A person who suffers a stroke loses 1.9 million neurons every minute that a stroke is untreated, says Prof. Leker, and “so we say ‘Time is brain.’ ” About 15-30 percent of individuals who experience a stroke are permanently disabled; they are unable to walk, talk clearly or feed themselves. Finding a means to regenerate the damaged blood vessels and nerve cells could give a new lease on life to hundreds of thousands of people around the world.  

Comments

From: Camille on August 20, 2015
Could this treatment also help a person who has had a TBI and is left hemiplegic
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Wednesday, May 23 2018

From Legacy to Innovation: The Vision of Hadassah’s New Division of Nursing Director

Rely Alon, PhD, the new director of the Hadassah Medical Organization’s Division of Nursing and Health Professions, has a vision: “to bring Hadassah’s nurses to the forefront of leadership and to the spearhead of nursing in Israel.”

READ MORE ›
alt_text

Monday, May 7 2018

Hadassah Cardiac Specialists Are Collaborating with Colleagues to Save Syrian Children

In an effort to save the lives of Syrian children suffering from life-threatening and complex heart abnormalities, the Hadassah Medical Organization and the Baruch Padeh Medical Center in Poriya-Tiberias have launched a unique collaboration as part of the Israel Defense Forces’ Good Neighbor program.

READ MORE ›
alt_text

Monday, May 7 2018

Pluristem Stem Cell Therapy, Based on Hadassah Preclinical Research, Has Been Cleared by FDA

Pluristem Therapeutics has announced that its new cell therapy to treat acute radiation syndrome (PLX-R18), based on the pioneering studies performed within the laboratory of Prof. Raphael Gorodetsky at the Hadassah Medical Organization, has received clearance from the United States Food and Drug Administration to treat individuals who may have been acutely exposed to high-dose radiation as the result of a nuclear attack or accident.

READ MORE ›
alt_text

Thursday, May 3 2018

HMO Exclusive Call with Nurse Rely Alon

Please join us for an exclusive conference call with Dr. Rely Alon, Director, Division of Nursing & Health Professions, Wednesday May 9, 2018 from 10:00 - 11:00 am EDT

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More